Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 2.6% year on year to $249.3 million. Its GAAP loss of $0.31 per share was 3.6% above analysts’ consensus estimates.
Is now the time to buy TNDM? Find out in our full research report (it’s free for active Edge members).
Tandem Diabetes (TNDM) Q3 CY2025 Highlights:
- Revenue: $249.3 million vs analyst estimates of $236 million (2.6% year-on-year growth, 5.6% beat)
- EPS (GAAP): -$0.31 vs analyst estimates of -$0.32 (3.6% beat)
- Adjusted EBITDA: $2.77 million vs analyst estimates of $5.55 million (1.1% margin, 50% miss)
- Operating Margin: -9.2%, up from -10.7% in the same quarter last year
- Sales Volumes fell 4.8% year on year (24.7% in the same quarter last year)
- Market Capitalization: $900.7 million
StockStory’s Take
Tandem Diabetes’ third quarter was marked by improved operational efficiency and commercial execution, resulting in a positive market reaction. Management credited the quarter’s performance to the ongoing modernization of U.S. commercial operations, increased pricing contributions from both traditional and pharmacy channels, and early traction from new product offerings. CEO John Sheridan highlighted that changes in sales processes and organizational restructuring began to yield tangible results, particularly through better sales productivity and a strong mix of customers adopting both t:slim and Mobi pump platforms. The company’s focus on expanding pharmacy benefit access and a growing portfolio approach helped offset volume headwinds and supported margin improvements.
Looking forward, Tandem Diabetes’ outlook is grounded in expanding pharmacy access, further product launches, and direct international operations. Management expects new product introductions—such as Mobi Tubeless and further integration with continuous glucose monitoring (CGM) systems—to drive customer growth, particularly among people transitioning from multiple daily injections. CFO Leigh Vosseller emphasized that, “the combination of price, channel benefit and scaling reductions in Mobi costs underpin both our near- and long-term gross margin goals.” The company is also prioritizing a fully closed-loop pump system and expects its multichannel approach to enhance both top-line and margin performance as it enters new international markets and broadens U.S. pharmacy contributions.
Key Insights from Management’s Remarks
Management attributed the quarter’s progress to commercial modernization, product portfolio expansion, and a shift toward pharmacy channel sales, all of which contributed to improved financial performance and set up future growth opportunities.
- Commercial operations overhaul: Ongoing restructuring and the deployment of new technology platforms have improved sales productivity, with the company seeing early benefits in U.S. sales efficiency and effectiveness.
- Pharmacy channel momentum: Expansion of pharmacy benefit coverage for Mobi surpassed 40% of U.S. lives, and the initial rollout of t:slim supplies through pharmacy channels was met with encouraging early uptake, cited by customers as more affordable and convenient.
- Portfolio-driven adoption: Two-thirds of new customers came from people previously using multiple daily injections, with both t:slim and Mobi showing strong adoption. This highlights the value of a diverse pump portfolio in a segmented diabetes technology market.
- International direct sales preparation: Tandem is transitioning to direct operations in Europe, beginning with the U.K., Switzerland, and Austria in early 2026. Direct sales are expected to drive higher selling prices and margin expansion compared to distributor-based models.
- Margin improvement initiatives: Gross margin improvement was driven by higher average selling prices and a growing share of pharmacy sales. Organizational restructuring and cost discipline, particularly in R&D and stock-based compensation, also contributed to operating leverage.
Drivers of Future Performance
Tandem Diabetes’ guidance is underpinned by expanded pharmacy access, new product launches, and direct market entry in Europe, with management focused on sustainable revenue growth and margin improvement.
- Pharmacy channel expansion: Management expects further pharmacy benefit penetration to enhance both top-line growth and gross margins as more customers transition to this channel, supported by expanded contracts with major pharmacy benefit managers (PBMs).
- Product innovation pipeline: Upcoming launches such as Mobi Tubeless, fully closed-loop pump algorithms, and expanded CGM integrations are projected to drive new patient uptake—especially among users transitioning from multiple daily injections and Type 2 diabetes patients.
- International strategy execution: The move to direct sales in select European countries is anticipated to boost average selling prices and margins. However, management noted risks from distributor inventory adjustments and potential competitive dynamics as more players enter pharmacy channels.
Catalysts in Upcoming Quarters
Looking ahead, the StockStory team will be watching (1) the pace of pharmacy channel adoption and its impact on gross margins, (2) the commercial rollout and patient uptake of new products like Mobi Tubeless and expanded CGM integrations, and (3) the successful transition to direct sales in key European markets. Execution of the multichannel market access strategy and incremental operating leverage will also be critical for sustained improvement.
Tandem Diabetes currently trades at $15.36, up from $13.32 just before the earnings. Is there an opportunity in the stock?See for yourself in our full research report (it’s free for active Edge members).
Stocks That Trumped Tariffs
Fresh US-China trade tensions just tanked stocks—but strong bank earnings are fueling a sharp rebound. Don’t miss the bounce.
Don’t let fear keep you from great opportunities and take a look at Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.